Hugo Brugière
Chairman and CEO

Hugo is a graduate of the Saint-Cyr Special Military School and SciencesPo Paris. A serial entrepreneur with more than twenty companies to his credit, he has specialized for several years in stock market and restructuring/turnaround with listed companies.
Current Chairman and CEO of Neovacs, Hugo also exercises numerous mandates in different companies in France and around the world (ARCTURUS GROUP, BISTROTS PAS PARISIENS, CYBERGUN, KEYMEX, etc.).
Former general delegate of the Employers' Organization of Accountants and Auditors, he has also served several prominent political figures. As Reserve Officer, he commanded a company in the 19th Engineer Regiment of Besançon.
The companies he manages today have approximately 700 employees for an overall turnover of nearly 60 million euros.

Vincent Serra
CSO and COO

Vincent Serra, 51 years old, PhD in Immunology, is senior manager with more than 20 years of experience in biotechnology, particularly in the field of immunotherapy. He is the author of several patents and scientific papers published in the field of vaccines. Before joining Neovacs as Scientific Director in January 2019, he was responsible for external innovation at Pierre Fabre, and executive Director of its Innovation Fund. Vincent Serra has also held the positions of Scientific Director, Managing Director and co-founder of various biotechnology companies. During his career, he has set up many licensing agreements, developed various products up to the clinical development, and participated in Abivax creation and IPO.

Bernard Fanget
VP Pharmaceutical Affairs

Bernard has extensive experience in the field of vaccines after many years leading teams in development and production at Sanofi Pasteur as Corporate Vice-President of Global Industrialization division. He has developed and registered many vaccines in Europe and USA. He was Senior Vice-President in charge of pharmaceutical development and Quality at Flamel Technologies.

Bernard shares his knowledge and skills as a consultant for various vaccine companies and Start-Ups in Europe, Asia and North America. Additionally, he has been CEO of many Start-Ups. Bernard is a member of the COVID 19 Vaccine Scientific Council where he brings his industrial knowledge, and he is also a member of various working groups at the World Health Organization.

Bernard has a PhD in Biochemistry from the Claude Bernard University - Lyon, France.

Olivier Dhellin
Director of Pharmaceutical Development

Olivier is responsible for pharmaceutical development (CMC) and quality assurance, as well as compliance with GMP Guidelines. CMC activities include Neovacs technology transfer from R&D department to external partners, all steps of production and analytical development, and interactions with partners under license agreement for any questions related to CMC. Olivier brings his expertise in immunotherapy as well as in vaccine development, experience learned previously in the Franco-American Company, Anosys, dedicated to the development of acellular vaccines derived from dendritic cells. Prior to his industrial career, he was an academic scientist in molecular biology and genomics at Gustave Roussy Institut, and held a post-doctoral position in molecular pharmacology at Pasteur Institut. Olivier has a PhD in Virology (Pierre and Marie Curie University, France) and is also a Pharmacist (graduated from Paris XI University, France) who acquired notable experience in the hospital environment during his internship.

Maria Menard
Regulatory Affairs Project Manager and Medical Writer

After a PhD in Genetics and Physiology of Microorganisms (University Paris XI, France) and a post-doctoral position at Columbia University (NYC, USA), Maria held several positions in clinical research, including medical writer (Sanofi), clinical studies manager (CRO/Umanis and DBV Technologies), and regulatory affairs manager (INSERM). Maria joined Neovacs in 2018, where she is responsible for writing regulatory documents (e.g, ODD, IB, DSUR). She is in charge of submissions to high authorities (FDA and EMA) and ethics committees, and has worked with the ANSM for scientific advice. In addition, Maria participates in the clinical studies development plan and supports activities to assess the clinical relevance of the results, in particular monitoring outsourced activities (CROs, statistics, pharmacovigilance, central laboratory).

Alexandre Courtoux

Alexandre Graduated from the Leonard de Vinci School of Management.

After more than 5 years of experience in an audit and financial consulting firm, Alexandre COURTOUX has been involved for more than 3 years in the turnaround operations of the CYBERGUN Group.

He has also joined the HBR INVESTMENT GROUP team since summer 2020, and is in charge of management of the financial departments.